Oncology Institute (NASDAQ:TOI) Stock Price Down 6.9% – Time to Sell?

Shares of The Oncology Institute, Inc. (NASDAQ:TOI) were down 6.9% on Thursday . The company traded as low as $0.88 and last traded at $0.89. Approximately 259,349 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 848,664 shares. The stock had previously closed at $0.96.

Oncology Institute Stock Performance

The business has a fifty day simple moving average of $0.57 and a two-hundred day simple moving average of $0.39. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The company has a market cap of $67.54 million, a P/E ratio of -1.15 and a beta of 0.37.

Insiders Place Their Bets

In related news, Director Brad Hively purchased 250,000 shares of Oncology Institute stock in a transaction on Tuesday, November 26th. The stock was acquired at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the completion of the transaction, the director now directly owns 616,753 shares in the company, valued at $104,848.01. This represents a 68.17 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Oncology Institute

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in shares of Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after purchasing an additional 12,000 shares in the last quarter. HighTower Advisors LLC grew its position in shares of Oncology Institute by 190.8% during the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after purchasing an additional 53,382 shares in the last quarter. Jane Street Group LLC grew its position in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after purchasing an additional 109,769 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Oncology Institute during the fourth quarter worth about $41,000. Finally, Tiff Advisory Services LLC grew its position in shares of Oncology Institute by 13.2% during the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock worth $921,000 after purchasing an additional 346,256 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.